Results 261 to 270 of about 752,857 (303)

Multi-drug Resistant Tuberculosis Management

2021
Rifampicin-resistant Tuberculosis (RR-TB) and Multidrug resistant Tuberculosis (MDR-TB) are a current global health threat, and are characterised by high mortality, chronic sequelae, complexity and high cost. The drug resistant form of this infectious disease was globally responsible for 600,000 new cases in 2017, with 161,000 cases being notified and ...
Simon Tiberi, Temi Lampejo, Alimuddin Zumla   +2 more
openaire   +1 more source

Multi-Drug-Resistant Pulmonary Tuberculosis

Drug Intelligence & Clinical Pharmacy, 1979
A case of multiple-drug-resistant pulmonary tuberculosis (TB) is presented. The patient's refusal to complete a course of drug therapy culminated in numerous relapses, treatment failures, and finally, death. Noncompliant drug behavior is probably the major cause of treatment failure.
Brock G. Guernsey, Michael R. Alexander
openaire   +1 more source

Bimetallic nanoparticles against multi-drug resistant bacteria

Chemical Communications, 2020
Bimetallic nanoparticles can fight multi-drug resistant (MDR) bacteria and treat wound infections caused by MDR bacteria.
Xiaohui Zhao, Yuexiao Jia, Ruihua Dong, Jinqi Deng, Hao Tang, Fuping Hu, Shaoqin Liu, Xingyu Jiang   +7 more
openaire   +2 more sources

[Multi-Drug-Resistant Pseudomonas Aeruginosa].

Rinsho byori. The Japanese journal of clinical pathology, 2019
Infection control is one of the most important measures for the safety of medical treatment. The microbiology unit of the clinical laboratory is the first defense against nosocomial infection. Our infection control team belongs to the clinical laboratory and our infection control practices are based on the accessibility of microbiology data.
openaire   +2 more sources

Multi-Drug-Resistant Tuberculosis

2004
Drug-resistant tuberculosis and, particularly, multidrug-resistant tuberculosis (MDR-TB; defined as strains of M. tuberculosis resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs), have recently received heightened attention in the media.
openaire   +1 more source

Multi-drug resistance and cancer

Expert Opinion on Therapeutic Patents, 2007
Development of drug resistance during chemotherapy is the leading cause of treatment failure and decreased survival in cancer patients. Drug resistance can occur in many ways, such as altering the targets or the metabolism of the drug, and multi-drug resistance is one of the most extensively studied forms for > 30 years.
openaire   +1 more source

Multi-Drug Resistance in Chronic Lymphocytic Leukemia

Leukemia & Lymphoma, 1999
We evaluated 45 chronic lymphocyte leukemia (CLL) patients for the presence of multi-drug resistance (MDR) by the ex vivo techniques: 1) a functional assay utilizing doxorubicin (dox) retention with modulation; 2) a cytotoxicity assay (MTT) with modulation; 3) and four monoclonal antibodies.
W R, Friedenberg, S K, Spencer, C, Musser, T F, Hogan, K A, Rodvold, D A, Rushing, J J, Mazza, D A, Tewksbury, J J, Marx   +8 more
openaire   +2 more sources

Multi-drug Resistant HIV-1

Journal of Infection, 2000
A S, Omrani, D, Pillay
openaire   +2 more sources

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

Ca-A Cancer Journal for Clinicians, 2021
Amila K Nanayakkara, Kevin Outterson
exaly  

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti   +2 more
exaly